That was such a great article.
Vantage is based in Redwood City, CA, a ten minutes' drive from NASA's Ames Research Center in the heart of Silicon Valley. The current company backed into a public vehicle formerly incorporated under the laws of the Republic of Seychelles in the Indian Ocean. Its bright beautiful founder Dr. Lisa Ramakrishnan wanted to provide universal access to quality affordable health care across sub-Sahara Africa with improved medicine, hospitals and clinics. Alas Wall Street preferred to do well rather than good. Few jumped to invest in a risky concept in a troubled area. So the founder took back all the operations and the debt but retained some shares. Today the new Vantage Health has about 150 million shares outstanding. The public float is about 20 million. Neither Vantage Health or its private parent Nanobeak, Inc. has any debt.
Vantage Health, Inc. is too new to make analysis very meaningful. If Vantage succeeds in attracting help from a big pharma, everything will look dramatically different two years from now.
Here is what Jeremy has to offer. Vantage's private parent Nanobeak, Inc. co- developed seven patents with NASA. Vantage Health received a sub-license on January 7, 2014 after NASA and Nanobeak entered into an exclusive 5-year license to commercialize mobile healthcare products derived from NASA patented chemical sensing technology and has an exclusive license for five years for this mobile healthcare use.
The license is renewable providing progress is made. So Jeremy would like to get an app device through clinical trials with the FDA by the end of this year or early next year. He guestimates that his team will need several million to get the job done.
Also prestigious Scripps Translational Science Institute formed a strategic partnership with Vantage for the advancement of Mobile Health Technology. Vantage is developing personalized and point-of-care screening using apps based upon chemical sensing residing within a small device attached to a smart phone.
STCI's Center for Digital Medicine is committed to the development and research of novel mobile health devices to accelerate their uptake into clinical practice. Together with Vantage they will collaborate in the planning and execution of clinical trials to prove the app can identify the particular volatile organic compounds exhaled commonly associated with lung cancer.
In a few years Jeremy hopes individuals will be able to monitor their own health using their own their smart phones. But the FDA has made it clear that the first step should be starting with established health care providers. They know the insurance procedures and have the contacts to jump start the process. Using established healthcare providers should simplify the launch considerably.
Imagine a world where deadly diseases like lung cancer could be screened for at the earliest stage in minutes by exhaling into an inexpensive small Bluetooth enabled device that works with any smart phone. Imagine once a cancer treatment protocol is started, the oncologist can monitor patient progress at any time just by having the patient exhale into that same device.
If identifying lung cancer early works, Jeremy has a stream of other uses he wants to attempt. But all that must stay on hold until Vantage proves itself with this first effort.
For more information please visit: www.vantagehealthinc.com. Investors should contact Christine J. Petraglia, Investor Relations, CSIR Group at 212-386-7082 or email: investors@csirgroup.com.
Market Data 
Markets 
AI
